The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study

Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study

March 28, 2020 • By Michael Putman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Data contradicting the conclusions of this study have already begun to emerge, including a single-center, open-label, randomized, controlled trial of 30 patients with COVID-19 recently published by Jun et al. in the Journal of Zhejiang University.5 Contrary to the paper by Gautret et al., this study found no significant difference with regard to viral clearance among patients who received hydroxychloroquine (13 of 15; 87%) or usual care (14 of 15; 93%). Neither study was adequately powered to address meaningful outcomes or serve as the basis for strong recommendations. Multiple larger randomized controlled trials are actively recruiting (ClinicalTrials.gov), but their results may not be available for many months.

You Might Also Like
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • FDA Accelerates Approvals of Generic Versions of HCQ
Explore This Issue
May 2020
Also By This Author
  • Improving Lupus Drug Regimen Adherence Among Minorities

In the meantime, it seems likely that hospital systems and providers will prescribe hydroxychloroquine to patients with COVID-19. Although the data supporting its use are of low quality, no studies to date have been sufficiently rigorous to refute this practice. Unpublished reports from China have reportedly been promising, and the preclinical mechanistic studies support the bioplausibility of hydroxychloroquine as a treatment for COVID-19. Many rheumatologists have become accustomed to recommending hydroxychloroquine as a generally well-tolerated therapy; we should forgive others for feeling similarly in the face of a pandemic. In the near term, at least, we will have to adapt to this new reality.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Adaptation does not mean acquiescence, however, and we should encourage rational use of hydroxychloroquine whenever possible. No data exist for prescribing hydroxychloroquine for post-exposure prophylaxis, and we should not prescribe it for this indication. Patients already taking hydroxychloroquine should be discouraged from sharing their valuable supply or from increasing their doses. For a patient with rheumatoid arthritis or lupus, the harm from running out of hydroxychloroquine seems likely to outweigh any possible benefit to others with regard to COVID-19. Finally, we and other providers should not write prophylactic prescriptions for ourselves or our family. We should be held to the same standards we recommend in practice, which dictate judicious use of this valuable medication.

In addition to avoiding these practices, we can take a number of positive steps to lessen the impact of hydroxychloroquine shortages:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Hydroxychloroquine has a half-life of many weeks, and in many cases, the answer to a few missed doses should be reassurance;
  • Build a list of pharmacies in your area that have supplies available, and be ready to direct your patients appropriately;
  • Engage with your medical center to ensure that patients with rheumatologic diseases have a voice at the table when treatment algorithms are created; and
  • Above all, be available. Prophylactic phone calls and responding quickly to patient queries will be necessary to assuage their reasonable concerns.

Reasons for optimism also exist. Enthusiasm for hydroxychloroquine at the highest level of government should encourage rapid escalation of production. Pharmaceutical companies, including Mylan, Teva, Amneal and Novartis, have pledged to produce or donate nearly 200 million doses. If these totals materialize or convincing data refute Gautret et al.’s findings, the supply of hydroxychloroquine should return to normal before our patients experience substantial harm.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Opinion Tagged With: COVID-19, HCQ, HYDROXYCHLOROQUINEIssue: May 2020

You Might Also Like:
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • FDA Accelerates Approvals of Generic Versions of HCQ
  • Tocilizumab Begins Clinical Trial for COVID-19

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)